PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31673238-4	2019	Human osteoblasts obtained by primary culture from bone samples were treated with celecoxib at doses of 0.75, 2, or 5muM for 24 h. The MTT technique was used to determine the effect on proliferation; flow cytometry to establish the effect on cell cycle, cell viability, and antigenic profile; and real-time polymerase chain reaction to measure the effect on gene expressions of the differentiation markers RUNX2, alkaline phosphatase (ALP), osteocalcin (OSC), and osterix (OSX).	Celecoxib	82-91	alkaline phosphatase, placental	Homo sapiens	413-433	
31673238-4	2019	Human osteoblasts obtained by primary culture from bone samples were treated with celecoxib at doses of 0.75, 2, or 5muM for 24 h. The MTT technique was used to determine the effect on proliferation; flow cytometry to establish the effect on cell cycle, cell viability, and antigenic profile; and real-time polymerase chain reaction to measure the effect on gene expressions of the differentiation markers RUNX2, alkaline phosphatase (ALP), osteocalcin (OSC), and osterix (OSX).	Celecoxib	82-91	alkaline phosphatase, placental	Homo sapiens	435-438	
28007462-6	2017	Celecoxib inhibited the expression of both RUNX2 and ALP by suppressing their promoter activity.	Celecoxib	0-9	alkaline phosphatase, placental	Homo sapiens	53-56